1421760-08-8

Basic information

• Product Name: C₂₅H₃₂N₂O₆
• Synonyms: C₂₅H₃₂N₂O₆
• CAS NO: 1421760-08-8
• Molecular Weight: 456.539
• Mol File: 1421760-08-8.mol

Chemical Properties

• CAS DataBase Reference: C₂₅H₃₂N₂O₆(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₅H₃₂N₂O₆(1421760-08-8)
• EPA Substance Registry System: C₂₅H₃₂N₂O₆(1421760-08-8)

Safety Data

• Hazardous Substances Data: 1421760-08-8(Hazardous Substances Data)

Upstream product

• 302-53-4 S(-)-carbidopa 
• 1421760-07-7 C₁₆H₂₂N₂O₄ 
• 1057663-21-4 2-(2,4-dimethoxyphenyl)acetaldehyde 
• 613-45-6 2,4-Dimethoxybenzaldehyde 

Downstream Products

• 1421760-09-9 C₂₈H₃₅ClN₂O₈ 
• 1421760-00-0 C₃₃H₄₆N₂O₈ 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISEASES

The invention relates to the compound of or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing neuromuscular disorders and neurodegenerative diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, or parenteral-administration, or syrup, or injection. Such compositions may be used to treatment or management of neuromuscular disorders and neurodegenerative diseases such as Parkinson's disease, scleroderma, restless leg syndrome, hypertension and gestational hypertension.

COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISORDERS

The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for treating or preventing neuromuscular disorders and neurodegenerative diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosaf intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment or management of neuromuscular disorders and neurodegenerative diseases such as Parkinson's disease, scleroderma, restless leg syndrome, hypertension and gestational hypertension.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISEASES

The disclosures herein provide compounds of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceuiicai compositions may be formulated for peroral administration, transdermal administration, transmucosal, syrups, topical, extended release, sustained release, or injection. Such compositions may be used to treatment of metabolic condition, neuromuscular disorders and neurodegenerative diseases or its associated complications.